CVS Health Corporation (NYSE:CVS) Stock Has Average Price Target of $109.64 According to Analysts

CVS Health Corporation (NYSE:CVS) has been given an average rating of “Moderate Buy” by the twenty-five ratings firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and twenty-two have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $109.46.

CVS has been the topic of several analyst reports. Cantor Fitzgerald reiterated a “neutral” rating on shares of CVS Health in a research note on Friday, October 9th. Robert W. Baird set a $107.00 price target on CVS Health in a report on Thursday, August 6th. Royal Bank Of Canada increased their price target on CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a research report on Thursday, July 9th. Piper Sandler set a $112.00 price target on CVS Health in a research report on Wednesday, September 9th. Finally, TD Cowen reiterated a “buy” rating on shares of CVS Health in a research note on Wednesday.

Hedge Funds Weigh In On CVS Health

Several large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in CVS Health in the 2nd quarter valued at about $12,747,462,000. State Street Corp lifted its holdings in CVS Health by 26.3% in the second quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator’s stock valued at $7,751,205,000 after acquiring an additional 15,604,883 shares during the period. Wellington Management Group LLP boosted its holdings in CVS Health by 49.8% during the second quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator’s stock worth $3,496,725,000 after buying an additional 11,233,381 shares in the last quarter. Bank of America Corp DE boosted its holdings in CVS Health by 148.0% during the second quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock worth $2,398,868,000 after buying an additional 13,836,701 shares in the last quarter. Finally, Pzena Investment Management LLC purchased a new stake in CVS Health during the second quarter worth about $1,217,558,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported Q3 adjusted earnings of $2.09 per share, above the $1.65 consensus estimate, while revenue rose 5.4% year over year to $108.4 billion. Management raised its 2026 adjusted EPS outlook to at least $8.20 from a prior range of $7.90–$8.10. CVS Q3 results and guidance
• Neutral Sentiment: The company plans to separate its retail pharmacy business from its health benefits, pharmacy-benefit and care operations, creating two publicly traded companies by the first half of 2028. CVS says the businesses could gain focus and strategic flexibility, though the separation is still more than a year away. CVS breakup plan
• Negative Sentiment: The breakup announcement appears to be the main overhang: investors are reacting warily to CVS reversing its vertically integrated strategy, including the Aetna combination, despite the earnings beat. The scale and complexity of unwinding the businesses may be fueling uncertainty around execution and the value of the new structure. Market reaction to CVS split plan

CVS Health Stock Performance

NYSE CVS opened at $79.90 on Friday. The company has a market cap of $102.19 billion, a P/E ratio of 21.14, a P/E/G ratio of 0.85 and a beta of 0.58. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The stock has a 50-day moving average of $90.82 and a two-hundred day moving average of $88.86. CVS Health has a 1-year low of $69.51 and a 1-year high of $110.68.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.65 by $0.44. The company had revenue of $108.40 billion for the quarter, compared to analyst estimates of $104.72 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.60 EPS. As a group, analysts anticipate that CVS Health will post 8.02 EPS for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd were issued a $0.6650 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date was Thursday, October 22nd. CVS Health’s dividend payout ratio (DPR) is presently 70.37%.

CVS Health Company Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.